The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital

Posted: December 18, 2022 at 12:22 am

NEW YORK and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), today announced the first cohort of the atai Fellowship Fund in Psychedelic Neuroscience (the “Fellowship Fund”) at Massachusetts General Hospital (“MGH”) Center for the Neuroscience of Psychedelics. The $2 million Fellowship Fund was announced in December 2021 to facilitate research into the potential of psychedelics to address unmet patient needs in mental health and support promising graduate students and other trainees in furthering their professional careers in this emerging field.

Read the rest here:
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital

Related Posts